Pay in 4 interest-free payments of $6.09 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
Diabetes, Obesity and Metabolism, 16(1), 921
Compounded tirzepatide is not recommended for patients with a history of thyroid cell tumors such as medullary thyroid cancer (MTC) and MEN 2 syndrome (Multiple endocrine neoplasia type 2 syndrome)
The drug molecule may attain a privileged status in the antidiabetic market as the clinical data showed that it effectively reduces HbA1c level in monotherapy as well as in add-on therapy, compared to placebo, semaglutide, insulin degludec, and insulin glargine, and found effective in type 2 diabetes associated conditions like atherogenic dyslipidemia and non-alcoholic steatohepatitis
Your provider decides the schedule based on your blood tests and symptoms
Ready to finally see results on the scale and in the mirror
